精神分裂症患者脑内神经炎症的PET显像:TSPO配体研究
该研究用[11C](R)-PK11195 PET测量20例近期起病和21例稳定期精神分裂症患者及21名健康对照的TSPO结合潜力,发现诊断与TSPO无显著关联,年龄影响更大;未用药近期起病患者TSPO低于对照,提示小胶质细胞发育或功能受损,抗精神病药可能逆转。
要点
- 精神分裂症诊断与TSPO结合潜力无显著关联,年龄影响更大。
- 未用药近期起病患者TSPO低于对照,用药者无此差异。
- 稳定期患者TSPO与阳性症状负相关、与阴性症状正相关。
核心结论
- 衰老与TSPO升高相关,但精神分裂症诊断本身不与TSPO升高相关。
- 未用药近期起病患者TSPO低于正常,可能反映小胶质细胞发育或功能受损,抗精神病药治疗可能抵消此改变。
研究设计与样本
- 研究纳入20例近期起病精神分裂症患者(14男)、21例稳定期患者(13男)和21名健康对照,患者多接受抗精神病药治疗。
- 所有参与者接受TSPO特异性放射性配体[11C](R)-PK11195 PET扫描,主要结局为前扣带皮层结合潜力BPND,次要结局为其他六个脑区BPND。
主要发现
- 前扣带皮层平均BPND在年龄较大者(稳定期患者和对照)高于年龄较小者(近期起病患者和对照),但近期起病或稳定期患者与各自年龄匹配对照间无显著差异(ANOVA诊断主效应F1,58=0.407,p=0.526)。
- 与对照相比,未用药近期起病患者(n=6)BPND较低,而用药患者无此差异。
- 稳定期患者BPND与阳性症状负相关,与阴性症状评分正相关。
临床怎么用
- 当前TSPO PET证据不支持将神经炎症作为精神分裂症诊断的普遍标志。
- 未用药近期起病患者TSPO偏低提示免疫机制可能涉及小胶质细胞功能异常,需结合用药状态解读。
局限性
- 患者多接受抗精神病药治疗,未用药样本量小(n=6)。
- 需开发针对特定免疫机制的新型放射性配体以进一步阐明。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Positron emission tomography (PET) imaging of the 18 kDa translocator protein (TSPO), which is upregulated in activated microglia, is a method for investigating whether immune activation is evident in the brain of adults with schizophrenia. This study aimed to measure TSPO availability in the largest patient group to date, and to compare it between patients with recent onset (ROS) and established (ES) schizophrenia. In total, 20 ROS patients (14 male), 21 ES (13 male), and 21 healthy controls completed the study. Patients were predominantly antipsychotic-medicated. Participants underwent a PET scan using the TSPO-specific radioligand [11C](R)-PK11195. The primary outcome was binding potential (BPND) in the anterior cingulate cortex (ACC). Secondary outcomes were BPND in six other regions. Correlations were investigated between TSPO availability and symptom severity. Data showed that mean BPND was higher in older (ES and controls) compared with younger (ROS and controls) individuals, but did not significantly differ between ROS or ES and their respective age-matched controls (ACC; ANOVA main effect of diagnosis: F1,58 = 0.407, p = 0.526). Compared with controls, BPND was lower in antipsychotic-free (n = 6), but not in medicated, ROS patients. BPND in the ES group was negatively correlated with positive symptoms, and positively correlated with negative symptom score. Our data suggest ageing is associated with higher TSPO but a diagnosis of schizophrenia is not. Rather, subnormal TSPO levels in drug-free recent-onset patients may imply impaired microglial development and/or function, which is counteracted by antipsychotic treatment. The development of novel radioligands for specific immune-mechanisms is needed for further clarification.
引用
- Conen S, Gregory CJ, Hinz R, et al. Neuroinflammation as measured by positron emission tomography in patients with recent onset and established schizophrenia: implications for immune pathogenesis. Mol Psychiatry. 2020. PMID: 32606376. doi:10.1038/s41380-020-0829-y
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。